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ABSTRACT
Objectives: Dopamine plays a critical role in various vital functions, including hormonal regulation, reward, emotions, and food intake. It affects on 
the multiple aspects of food intake that include food selection, satiety, and energy expenditure. Dopamine D2 receptors (D2R) were found to be lower 
in several brain regions in both obese experimental animals and humans, and it has been observed that dopamine D2 agonist bromocriptine (BC) can 
exert favorable metabolic changes in seasonal obesity. The aim of this study was to investigate the beneficial effect of chronic administration of BC a 
central dopamine receptor agonist on body weight gain, adiposity, and biochemical anomalies in rats.
Methods: In this study, chronic administration of BC (2.5 and 5 mg/kg/day, i.p) a dopamine agonist for 8 weeks along with high-fat diet (HFD) to the 
obese rats which were pretreated with HFD feeding for 8 weeks on the various parameters of obesity were analyzed. The effects of these treatments on 
body weight, feed intake (kcal), weight and size of fat pads, levels of serum glucose, triglycerides (TG), total cholesterol (TC), high-density lipoproteins 
(HDL), and low-density lipoprotein were analyzed.
Results: Treatment with BC (2.5 and 5 mg/kg/day, i.p) produced significant dose-dependent decrease (p<0.05) in body weight gain, feed intake (kcal), 
weight and size of fat pads, levels of serum glucose, TG, TC, and low-density lipoproteins as compared to HFD group. Moreover, the level of serum 
HDL was increased as compared to HFD group. BC a dopamine receptor agonist positively modulate the parameters of obesity, and the effect was 
comparable to orlistat, a well-reported drug for obesity.
Conclusion: In conclusion, the study demonstrates that BC ameliorated established obesity and associated biochemical consequences.
Keywords: Obesity, Bromocriptine, High-fat diet, Dopamine.
INTRODUCTION
Obesity has become a serious and rising public health problem 
worldwide, affecting people across all ages, sex, ethnicities and 
races and its prevalence has been increasing at an alarming 
rate [1]. It is no more viewed as a cosmetic issue, but it becomes 
a potential risk factor of various comorbidities, such as type 2 
diabetes, cardiovascular morbidity, and cancer [2,3]. Excessive fat 
accumulation in the body not only adversely affect on health but also 
impaired the quality of life, and it presents a significant challenge to 
future health-care budgets [4,5]. The psychological consequences are 
also severe and include body image disparagement and among the 
severely obese, depression [6-8]. Obesity is an imbalance between 
energy intake and expenditure [9], i.e., more food is consumed than 
utilized, leading to excess fat stores being laid down. Freely available 
high-calorie food, sedentary lifestyle and many environmental 
factors predispose individuals to gain weight. Genetic factors also 
contribute to this imbalance [10]. In the severely obese, surgical 
intervention may be necessary. An alternative approach is to develop 
therapeutic agents that can either reduce food consumption or 
increase energy utilization. Despite intensive research on obesity 
pathogenesis, an effective therapeutic strategy to treat and cure 
obesity is still lacking. At present, only a few FDA-approved anti-
obesity drugs such as orlistat, lorcaserin, phentermine-topiramate, 
and naltrexone-bupropion are available in the market, but they have 
considerable side effects [11]. Exciting studies in past decades have 
established the importance of neural pathway in the hypothalamus 
in the regulation of body weight homeostasis. Recent research 
significantly expanded the list of neurotransmitters involved in body 
weight regulating neural pathways [12]. Understanding the function 
of neurotransmitters released from key neurons for energy balance 
regulation is essential for delineating neural pathways and eventually 
for designing effective therapeutic drugs against the obesity epidemic. 
Considerable efforts have been devoted to the development of weight 
control medications that target neurotransmitters in the brain that 
regulate food intake [13]. Several neurotransmitters (dopamine, 
GABA, norepinephrine, and serotonin), as well as peptides and 
amino acids, are involved in the regulation of food intake [14]. 
The cerebral mechanisms underlying the behaviors that lead to 
pathological overeating and obesity are poorly understood [15]. 
Dopamine, a neurotransmitter in the mammalian brain plays, 
a critical role in various vital functions, including hormonal 
regulation, reward, emotions, and food intake. It affects on the 
multiple aspects of food intake that include food selection, satiety, 
and energy expenditure [16,17]. Several lines of research indicate 
that abnormal dopaminergic neurotransmission could be involved 
in pathophysiological processes leading to obesity. Most of these 
studies are focused on the hypothalamic dopamine transmission that 
is believed to play a pivotal role in the guidance of fuel flux and energy 
homeostasis [18]. In general, these investigations have indicated a 
decreased dopaminergic signaling in obese subjects. For example, 
dopamine D2 receptors (D2R) were found to be lower in several 
brain regions in both obese experimental animals and humans, and 
it has been observed that dopamine D2 agonist bromocriptine (BC) 
can exert favorable metabolic changes in seasonal obesity [19]. The 
aim of this study was to investigate the beneficial effect of chronic 
administration of BC a central dopamine receptor agonist on body 
weight gain, adiposity, and biochemical anomalies in rats.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i6.17843
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METHODS
Drugs and chemicals
Casein (Modern Diary, New Karnal, India) and cholesterol (Thomas 
Baker, Mumbai, India) were used to prepare high-fat diet (HFD). BC 
was purchased from local market. Orlistat (Sigma-Aldrich) is (S)-2-
formylamino-4-methyl-pentanoic acid (S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-
oxetanyl]methyl]dodecyl ester. All the drugs were dissolved in dimethyl 
sulfoxide (DMSO; 10%, v/v). The estimation kits for serum glucose, 
cholesterol, triglycerides (TG), and high-density lipoproteins (HDL) 
were obtained from (Reckon Diagnostics [P] Ltd. Vadodara, India). All 
other chemicals used in this study were of analytical grade. All drug 
solutions were freshly prepared before use.
HFD-induced obesity
Experimental obesity was induced by feeding HFD (containing; 
powdered normal chow [NC], 365 g; lard, 310 g; casein, 250 g; 
cholesterol, 10 g; vitamin mix and mineral mix, 60 g; dl-methionine, 
03 g; yeast powder, 01 g; NaCl, 01 g were added to make 1.0 kg of diet) 
to rats [20]. The HFD contained 5.33 Kcal/g while the NC contains 
3.80 Kcal/g. This diet provides 68% energy as carbohydrate, 20% as 
protein and 12% as fat to produce obesity in rats while as NC provides 
65% of energy as carbohydrate, 20% as protein, and 4% as fat [21].
Animal treatment
Male Wistar rats of 7-8 weeks of age were procured from the animal 
facility of the Institute. The animals were housed in polypropylene 
cages (two rats/cage) and maintained under controlled room 
temperature (25±2°C) with 12:12 hrs light and dark cycle. The 
guidelines of Committee for the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), Government of India were followed, 
and prior permission was sought from the Institutional Animal Ethics 
Committee for conducting the study. Animals were fed with NC or 
HFD for 8 weeks. Animals were divided into different groups and each 
group contained 6 animals. Animals fed on NC were continued on the 
same diet for further 8 weeks and were assigned as Group 1. HFD fed 
animals randomized on the basis of their body weight and divided into 
different 5 groups (Group 2-6), and these groups were continued on 
HFD for another 8 weeks. Group 2 was not given any treatment and 
assigned as HFD control. Group 3 was given DMSO 1 ml/kg day−1, 
i.p [22] and assigned as vehicle control. Group 4 was given orlistat 
30 mg/kg day−1, p.o. [21] and assigned as a standard control. Groups 5 
and 6 were given BC 2.5 and 5 mg/kg day−1, i.p, respectively [23]. All 
the animals had free access to water, and the animals were inspected 
daily. Food intake and body weight were measured twice weekly. At the 
end of the stipulated period, blood for various biochemical parameters 
was obtained by retro-orbital puncture under light ether anesthesia, 
and the animals were sacrificed by cervical dislocation. The blood was 
collected into tubes, serum separated, and analyzed on the same day. 
The epididymal, mesenteric, and retroperitoneal white adipose tissue 
(WAT) were dissected, cleaned of, weighed and stored in 10% buffered 
formalin solution for histological analysis. Lee index [24], i.e., (Body Wt 
in g) 1/3/(ano-nasal length in cm) an index of obesity, was calculated at 
the end of the experiment.
Histological analysis and morphometry
Epididymal adipose tissue was fixed in 10% formalin and then 
embedded with paraffin. Tissue sections (10 μm) were cut and 
mounted on microscope slides. After being air-dried, they were stained 
with hematoxylin and eosin and photographed at ×100 magnification. 
At least two fields per slice and six slices per fat mass were analyzed for 
the purpose of quantifying adipocyte size.
Measurements
Serum glucose, TG, total cholesterol (TC), and HDL cholesterol 
concentrations were measured using commercially available kits.
Statistical analysis
All values are expressed as mean ± standard deviation (SD). The 
significance of the differences between the means of various groups 
was established by one-way ANOVA with a Tukey’s post hoc test using 
the GraphPad Prism 4 software. The p<0.05 was considered to be 
statistically significant.
RESULTS
Administration of HFD for 8 weeks significantly (p<0.05) increased 
body weight of animals then the age-matched normal control rats, and 
there was no significant difference of body weights of animals between 
the various treatment groups before initiation of treatment (Table 1).
Effect of various pharmacological interventions on body weight, 
adipose tissue weight, and lee index
Obese rats after 16 weeks of HFD feeding had significantly increased 
body weight and total fat content then the age-matched normal 
control rats (Fig. 1a and b). Lee index was also significantly increased 
in obese rats as compared to normal rats (Fig. 1c). However, 
treatment with BC (2.5 and 5 mg/kg) from 9 to 16 weeks attenuated 
HFD induced increase in body weight, adipose pads weight, and lee 
index. Administration of DMSO (10% v/v DMSO, 1 ml/kg) from 9 to 
16 weeks did not affect HFD induced increase in body weight, adipose 
pads weight, and lee index. Administration of orlistat (30 mg/kg) a 
standard drug of obesity from 9 to 16 weeks produced a significant 
reduction in body weight gain, adipose pads weight, and lee index in 
obese rats (Table 2).
Effect of various pharmacological interventions on biochemical 
parameters
Obese rats after 16 weeks of HFD feeding had higher glucose, TG, and 
TC level as compared to the age-matched normal control rats (Fig. 1d-f). 
However, treatment with BC (2.5 and 5 mg/kg) from 9 to 16 weeks 
attenuated HFD induced hyperglycemia, hypertriglyceridemia, and 
hypercholesterolemia. Administration of DMSO (10% v/v DMSO, 1 ml/
kg) from 9 to 16 weeks did not affect HFD induced hyperglycemia, 
hypertriglyceridemia, and hypercholesterolemia. Administration of 
orlistat (30 mg/kg) a standard drug of obesity from 9 to 16 weeks 
produced a significant reduction in the level of glucose, TG, and TC in 
obese rats (Table 2).
Effect of various pharmacological interventions on adipocyte size
Histological examination of epididymal WAT revealed that HFD fed rats 
had markedly increased adipocyte size than did NC - fed rats. BC (2.5 
and 5 mg/kg) or orlistat (30 mg/kg) markedly suppressed epididymal 
adipocyte size compared to HFD fed rats. While DMSO (10% v/v DMSO, 
1 ml/kg) did not suppressed these adipose tissue size as compared to 
HFD rats (Fig. 2).
Table 1: Body weight of animals at 0 week, at the end of 8th week and at the end of 16th week
Groups Initial body weight Body weight at the end of 8th week Body weight at the end of 16th week
NC 222±9.3 242±13.5 282±17.8
OHFD-C 233±8.1 312.1±5.03a 399±16.2a
Vehicle control (10% v/v DMSO, 1 ml/kg) 234.3±7.9 316.3±8.5a 397±13a
Orlistat (30 mg/kg) 236±11.9 309.5±13.6a 299±14.6b
Bromocriptine (2.5 mg/kg) 229±12.8 318±5.7b 324.5±11.6b
Bromocriptine (5 mg/kg) 228.6±10.8 311±13.7b 305.3±13.29b
All values are expressed as mean±SD, n=6, one-way ANOVA followed by Tukey’s multiple range test. DMSO: Dimethyl sulfoxide. ap<0.05 versus NC: Normal control, 
bp<0.05 versus OHFD-C: Obese high-fat diet control, SD: Standard deviation
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Effect of various pharmacological interventions on daily feed 
intake (Kcal)
In HFD model, a significant increase (p<0.05) in feed consumption 
(Kcal) was observed as compared to NC-fed rats (Fig. 1g). Orlistat 
(30 mg/kg) which was standard control in this study significantly 
decreases the feed consumption as compared to HFD fed rats. 
Administration of DMSO (10% v/v DMSO, 1 ml/kg) from 9 to 16 weeks 
did not affect feed consumption of animals as compared to HFD fed rats. 
The food intake was significantly decreased by the administration of BC 
(2.5 and 5 mg/kg) from 9 to 16 weeks (Table 2).
DISCUSSION
In this study, experimental obesity was developed by long-term HFD 
treatment. HFD have been previously reported to increase energy 
intake and cause obesity in humans as well as animals [25,26]. The 
body weight gain observed in this study is consistent with studies in 
Fig. 1: Effect of high-fat diet (HFD) on various parameters in obese rats continued on HFD for further 8 weeks: (a) Increase in body weight, 
(b) total fat content, (c) Lee index, (d) serum glucose, (e) serum total cholesterol (TC), (f) serum triglycerides (TG), (g) daily feed intake 
in Kcal. All values are expressed as Mean ± Standard deviation, n=6, one-way ANOVA followed by Tukey’s multiple range test. TG, TC, 




Fig. 2: Effect of various pharmacological interventions on 
adipocyte size: (a) Adipocyte size of normal control animals, 
(b) adipocyte size of obese high-fat diet control animals, 
(c) adipocyte size of vehicle control animals, (d) adipocyte 
size of standard control animals, (e) adipocyte size of animals 
given BC 2.5 mg/kg day−1, (f) adipocyte size of animals given 
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animal models, suggesting that exposure to high concentrations of 
carbohydrates or HFD contribute to the development of overweight 
or obesity [27]. Notably, metabolic disturbance results in elevation of 
plasma lipids [28] which is characterized by elevated TC, TG levels, 
low-density lipoprotein cholesterol (LDL-C) levels, and decreased 
serum HDL-C [29]. Further, feeding with HFD caused hyperglycemia in 
rats [30]. Therefore, the serum lipid levels (TC, LDL, very LDL [VLDL], 
HDL, and TG) and glucose levels were estimated in this study as the 
marker of hyperlipidemia and hyperglycemia.
There is a relationship between HFD intake and neurotransmitter 
concentration in the rat brain [31]. Various reports showed that there is 
a lower dopamine D2R availability in the striatum of obese individuals 
than in normal individuals [15]. Earlier findings showed that the 
administration of dopamine agonists normalizes body weight in 
genetically obese mice [32]. BC is a D2R agonist shown to reduce BMI in 
individuals with prolactinomas [33]. Hence, this study was undertaken 
to examine the effect of BC in HFD induced obesity by peripheral 
administration of BC in two different doses, i.e., low and high dose. 
Our data demonstrated that in HFD rats, (1) high dose of BC treatment 
significantly reduced food intake, lee’s index, and body weight increase, 
(2) the weight of WAT was significantly decreased and the biochemical 
levels of glucose, TG, TC, LDL, and VLDL was significantly improved by 
high dose of BC treatment as compared to HFD rats. The high dose of BC 
was found to be more effective as compared to its low dose this result 
gives the evidence that BC prevents the progression of obesity from 
predisposed factors.
These findings suggested that reduction in food intake may be due to 
D2R agonism by BC. The decreased D2R in obese individuals perpetuate 
pathological eating as a means to compensate for the decreased 
activation of reward circuits, which are modulated by dopamine [34]. 
This may reflect direct hypothalamic effects that result in decreased 
appetite and/or be the consequence of increased sensitivity toward 
reward induced by D2R agonism, thereby reducing the need for food 
intake. Indeed, recent study reported that BC administration led to an 
increase in D2R binding in the lateral hypothalamus in obese leptin 
receptor deficient Zucker rats [35]. This increase in D2R binding after 
BC treatment was also observed in other regions such as the striatum, 
nucleus accumbens shell/core, and ventral tegmental area and was 
paralleled by decreases in food intake and adiposity. A previous study 
conducted using N-0437, a selective D2R agonist also supported the 
reduction in food intake induced by D2R agonism [36].
In this investigation, it has been observed that administration of BC 
in the low and high dose for 8 weeks to the obese rats which were 
pretreated with HFD feeding for 8 weeks positively alters the various 
other parameters of obesity. The BC showed their actions mainly due 
to decreased feed intake. Hence, it has been observed that BC plays 
major beneficial role in obesity. Although in this study we have focused 
on dopamine, it is important to point out that the regulation of body 
weight is complex and involves other physiological mechanisms and 
other neurotransmitters [14].
The results from this study have implications for the treatment of 
obesity since they would suggest that strategies aimed at improving 
dopamine function might be beneficial in the treatment of obese 
individuals. In animal models, exercise has been found to increase 
dopamine release, [37] and to raise D2R [38]. Further research to 
identify treatment approaches that enhance the function of the 
dopamine system as a means to promote long-term maintenance of 
weight control is warranted. This data demonstrate that D2R agonist 
has the potential to work by reduce food intake in obese rats. Hence, it 
has been observed that BC plays major beneficial role in obesity; also, 
this study has provided a rational pharmacological basis for the use of 
BC in obesity.
CONCLUSION
In conclusion, this data provide the first evidence that BC positively 
alters the various parameters of obesity. BC shows these affects by 
acting on dopaminergic receptor in the brain, it mainly decreases food 
intake in obese rats. These findings suggest that dopamine agonist BC 
could be new therapeutic reagents for obesity.
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